J Matthias Lohr

Summary

Affiliation: Karolinska Institutet
Country: Sweden

Publications

  1. Vujasinovic M, Valente R, Maier P, von Beckerath V, Haas S, Arnelo U, et al. Diagnosis, treatment and long-term outcome of autoimmune pancreatitis in Sweden. Pancreatology. 2018;: pubmed publisher
    ..Only one-quarter of patients exhibit on imaging the characteristic "sausage-like" pancreas (diffuse enlargement), approximately three-quarters had a focal mass that could be misdiagnosed as pancreatic malignancy. ..
  2. Norberg K, Nania S, Li X, Gao H, Szatmary P, Segersvard R, et al. RCAN1 is a marker of oxidative stress, induced in acute pancreatitis. Pancreatology. 2018;: pubmed publisher
    ..We demonstrated that Rcan1 is regulated by oxidative stress and identified RCAN1 as a potential diagnostic marker of AP. ..
  3. Haas S, Krins S, Knauerhase A, Löhr M. Altered bone metabolism and bone density in patients with chronic pancreatitis and pancreatic exocrine insufficiency. JOP. 2015;16:58-62 pubmed publisher
    ..05). Patients with chronic pancreatitis have osteoporosis, along with abnormal bone metabolism and reduced bone mineral density as measured by DXA and X-ray. PERT is associated with less osteopathy. ..
  4. Löhr J, Haas S, Kröger J, Friess H, Höft R, Goretzki P, et al. Encapsulated cells expressing a chemotherapeutic activating enzyme allow the targeting of subtoxic chemotherapy and are safe and efficacious: data from two clinical trials in pancreatic cancer. Pharmaceutics. 2014;6:447-66 pubmed publisher
    ..However, taking the data from both trials together, a total of nine of the 27 patients were alive after one year, and two of these nine patients were alive for two years or more. ..
  5. Verbeke C, Löhr M, Karlsson J, Del Chiaro M. Pathology reporting of pancreatic cancer following neoadjuvant therapy: challenges and uncertainties. Cancer Treat Rev. 2015;41:17-26 pubmed publisher
  6. Löhr J, Karimi M, Omazic B, Kartalis N, Verbeke C, Berkenstam A, et al. A phase I dose escalation trial of AXP107-11, a novel multi-component crystalline form of genistein, in combination with gemcitabine in chemotherapy-naive patients with unresectable pancreatic cancer. Pancreatology. 2016;16:640-5 pubmed publisher
    ..Accordingly, we suggest further studies with AXP107-11 in pancreatic cancer patients. ..
  7. Lohr J, Faissner R, Koczan D, Bewerunge P, Bassi C, Brors B, et al. Autoantibodies against the exocrine pancreas in autoimmune pancreatitis: gene and protein expression profiling and immunoassays identify pancreatic enzymes as a major target of the inflammatory process. Am J Gastroenterol. 2010;105:2060-71 pubmed publisher
    ..The objective was to identify novel markers of disease and to unravel the pathogenesis of AIP...
  8. Vujasinovic M, Valente R, Del Chiaro M, Permert J, Lohr J. Pancreatic Exocrine Insufficiency in Pancreatic Cancer. Nutrients. 2017;9: pubmed publisher
    ..Therefore, it is crucial to be aware of the mechanisms involved in the disease, to be able to diagnose pancreatic exocrine insufficiency early on, and to treat malnutrition appropriately, for example, with pancreatic enzymes. ..
  9. Vujasinovic M, Valente R, Thorell A, Rutkowski W, Haas S, Arnelo U, et al. Pancreatic Exocrine Insufficiency after Bariatric Surgery. Nutrients. 2017;9: pubmed publisher
    ..Appropriate pancreatic enzyme replacement therapy should be part of the treatment algorithm in patients with confirmed PEI or symptoms suggestive of this complication. ..